ADA had sidelined and dismissed low carb for so many decades it leaves them with little to no clinical expertise when it comes to leveraging on low carbs as a primary tool for T1D/T2D intervention.
It could still be an enormous challenge to overcome the boardroom inertia to provide any true low carbs support programs, except in her personal capacity, when they are possibly dominated by pharma execs.
But yes. It is a positive step in the right direction...